Drug Trial Radar · NCT04155580
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
68
Actual
Start
Jun 12, 2020
Primary completion
Jan 14, 2022
Study completion Jan 14, 2022
Sponsor
- Lead sponsor
- Astex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
Conditions
- Acute Myeloid Leukemia
Interventions
ASTX660Drug
Capsule for oral administration
ASTX727Drug
Tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Assessment: Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to 30 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Smilow Cancer Hospital
New Haven, Connecticut
Sylvester Comprehensive Cancer Center
Miami, Florida
Northside Hospital - The Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia
The University of Chicago Medical Center
Chicago, Illinois
Franciscan Health Indianapolis (Blood and Marrow Transplantation)
Indianapolis, Indiana
The University of Kansas Clinical Research Center
Fairway, Kansas
Mayo Clinic
Rochester, Minnesota
Roswell Park Comprehensive Cancer Center
Buffalo, New York
New York University Langone Health
New York, New York
Mount Sinai Medical Center
New York, New York
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.